BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 17479106)

  • 1. An HSV-1 amplicon system for prostate-specific expression of ICP4 to complement oncolytic viral replication for in vitro and in vivo treatment of prostate cancer cells.
    Lee CY; Bu LX; Rennie PS; Jia WW
    Cancer Gene Ther; 2007 Jul; 14(7):652-60. PubMed ID: 17479106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells.
    Lee CY; Rennie PS; Jia WW
    Clin Cancer Res; 2009 Aug; 15(16):5126-35. PubMed ID: 19671871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
    Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
    Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined HSV-1 recombinant and amplicon piggyback vectors: replication-competent and defective forms, and therapeutic efficacy for experimental gliomas.
    Pechan PA; Herrlinger U; Aghi M; Jacobs A; Breakefield XO
    J Gene Med; 1999; 1(3):176-85. PubMed ID: 10738566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineering cell lines for production of replication defective HSV-1 gene therapy vectors.
    Grant KG; Krisky DM; Ataai MM; Glorioso JC
    Biotechnol Bioeng; 2009 Mar; 102(4):1087-97. PubMed ID: 18828174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment of a novel foreign gene delivery system combining an HSV amplicon with an attenuated replication-competent virus, HSV-1 HF10.
    Zhang L; Daikoku T; Ohtake K; Ohtsuka J; Nawa A; Kudoh A; Iwahori S; Isomura H; Nishiyama Y; Tsurumi T
    J Virol Methods; 2006 Nov; 137(2):177-83. PubMed ID: 16854473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An oncolytic mutant of herpes simplex virus type-1 in which replication is governed by a promoter/enhancer of human papillomavirus type-16.
    Griffith C; Noonan S; Lou E; Shillitoe EJ
    Cancer Gene Ther; 2007 Dec; 14(12):985-93. PubMed ID: 17853922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HSV-1 infected cell proteins influence tetracycline-regulated transgene expression.
    Herrlinger U; Pechan PA; Jacobs AH; Woiciechowski C; Rainov NG; Fraefel C; Paulus W; Reeves SA
    J Gene Med; 2000; 2(5):379-89. PubMed ID: 11045432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus.
    Kohno SI; Luo C; Nawa A; Fujimoto Y; Watanabe D; Goshima F; Tsurumi T; Nishiyama Y
    Cancer Gene Ther; 2007 Nov; 14(11):918-26. PubMed ID: 17693992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased transcomplementation properties of plasmids carrying HSV-1 origin of replication and packaging signals.
    Berthomme H; Fournel S; Epstein AL
    Virology; 1996 Feb; 216(2):437-43. PubMed ID: 8607275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome.
    Saeki Y; Fraefel C; Ichikawa T; Breakefield XO; Chiocca EA
    Mol Ther; 2001 Apr; 3(4):591-601. PubMed ID: 11319922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Probasin promoter (ARR(2)PB)-driven, prostate-specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer.
    Kakinuma H; Bergert ER; Spitzweg C; Cheville JC; Lieber MM; Morris JC
    Cancer Res; 2003 Nov; 63(22):7840-4. PubMed ID: 14633711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons.
    Krisky DM; Wolfe D; Goins WF; Marconi PC; Ramakrishnan R; Mata M; Rouse RJ; Fink DJ; Glorioso JC
    Gene Ther; 1998 Dec; 5(12):1593-603. PubMed ID: 10023438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved packaging system for generation of high-level noncytotoxic HSV-1 amplicon vectors using Cre-loxP site-specific recombination to delete the packaging signals of defective helper genomes.
    Zaupa C; Revol-Guyot V; Epstein AL
    Hum Gene Ther; 2003 Jul; 14(11):1049-63. PubMed ID: 12885345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype.
    Fu X; Zhang X
    Cancer Res; 2002 Apr; 62(8):2306-12. PubMed ID: 11956088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour-specific triple-regulated oncolytic herpes virus to target glioma.
    Delwar ZM; Liu G; Kuo Y; Lee C; Bu L; Rennie PS; Jia WW
    Oncotarget; 2016 May; 7(19):28658-69. PubMed ID: 27070093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of cholangiocarcinoma with oncolytic herpes simplex virus combined with external beam radiation therapy.
    Jarnagin WR; Zager JS; Hezel M; Stanziale SF; Adusumilli PS; Gonen M; Ebright MI; Culliford A; Gusani NJ; Fong Y
    Cancer Gene Ther; 2006 Mar; 13(3):326-34. PubMed ID: 16138120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short hairpin RNA-mediated inhibition of HSV-1 gene expression and function during HSV-1 infection in Vero cells.
    Liu YY; Deng HY; Yang G; Jiang WL; Grossin L; Yang ZQ
    Acta Pharmacol Sin; 2008 Aug; 29(8):975-82. PubMed ID: 18664330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy.
    Coukos G; Makrigiannakis A; Montas S; Kaiser LR; Toyozumi T; Benjamin I; Albelda SM; Rubin SC; Molnar-Kimber KL
    Cancer Gene Ther; 2000 Feb; 7(2):275-83. PubMed ID: 10770637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.
    Aghi M; Rabkin SD; Martuza RL
    Cancer Res; 2007 Jan; 67(2):440-4. PubMed ID: 17234749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.